Literature DB >> 28713989

Effects of proton beam irradiation on mitochondrial biogenesis in a human colorectal adenocarcinoma cell line.

Byung Geun Ha1, Sung Suk Jung1, Yun Hee Shon1.   

Abstract

Proton beam therapy has recently been used to improve local control of tumor growth and reduce side-effects by decreasing the global dose to normal tissue. However, the regulatory mechanisms underlying the physiological role of proton beam radiation are not well understood, and many studies are still being conducted regarding these mechanisms. To determine the effects of proton beams on mitochondrial biogenesis, we investigated: mitochondrial DNA (mtDNA) mass; the gene expression of mitochondrial transcription factors, functional regulators, and dynamic-related regulators; and the phosphorylation of the signaling molecules that participate in mitochondrial biogenesis. Both the mtDNA/nuclear DNA (nDNA) ratio and the mitochondria staining assays showed that proton beam irradiation increases mitochondrial biogenesis in 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced aggressive HT-29 cells. Simultaneously, proton beam irradiation increases the gene expression of the mitochondrial transcription factors PGC-1α, NRF1, ERRα, and mtTFA, the dynamic regulators DRP1, OPA1, TIMM44, and TOM40, and the functional regulators CytC, ATP5B and CPT1-α. Furthermore, proton beam irradiation increases the phosphorylation of AMPK, an important molecule involved in mitochondrial biogenesis that is an energy sensor and is regulated by the AMP/ATP ratio. Based on these findings, we suggest that proton beam irradiation inhibits metastatic potential by increasing mitochondrial biogenesis and function in TPA-induced aggressive HT-29 cells.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28713989     DOI: 10.3892/ijo.2017.4067

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

1.  Repeated Aconitine Treatment Induced the Remodeling of Mitochondrial Function via AMPK-OPA1-ATP5A1 Pathway.

Authors:  Li-Zhen Qiu; Wei Zhou; Lan-Xin Yue; Yi-Hao Wang; Fei-Ran Hao; Peng-Yan Li; Yue Gao
Journal:  Front Pharmacol       Date:  2021-06-10       Impact factor: 5.810

2.  ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells.

Authors:  Sheng Zhou; Hongwei Xia; Huanji Xu; Qiulin Tang; Yongzhan Nie; Qi Yong Gong; Feng Bi
Journal:  J Exp Clin Cancer Res       Date:  2018-09-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.